Empresa Ultragenyx Pharmaceutical Inc.
Acciones
RARE
US90400D1081
Biotecnología e investigación médica
Mercado cerrado -
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
44,28 USD | -1,84 % | +0,39 % | -7,40 % |
23/04 | ULTRAGENYX PHARMACEUTICAL INC. : RBC Capital Markets mantiene su recomendación de compra | ZM |
15/04 | Transcript : Ultragenyx Pharmaceutical Inc. - Special Call |
Resumen de negocios
Número de empleados: 1 276
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Crysvita Royalty
42,1
%
| 22 | 6,0 % | 183 | 42,1 % | +742,02 % |
Crysvita
17,4
%
| 43 | 11,7 % | 76 | 17,4 % | +77,37 % |
Dojolvi
16,3
%
| 56 | 15,3 % | 71 | 16,3 % | +27,01 % |
Collaboration and License - Crysvita Collaboration Revenue in Profit-share Territory
16,1
%
| 215 | 59,2 % | 70 | 16,1 % | -67,58 % |
Mepsevii
7,0
%
| 21 | 5,7 % | 30 | 7,0 % | +47,51 % |
Evkeeza
0,8
%
| - | - | 4 | 0,8 % | - |
Collaboration and License - Daiichi Sankyo
0,3
%
| 8 | 2,1 % | 1 | 0,3 % | -80,76 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
North America
70,7
%
| 281 | 77,4 % | 307 | 70,7 % | +9,27 % |
Latin America
17,8
%
| 45 | 12,3 % | 77 | 17,8 % | +72,98 % |
Europe
10,9
%
| 36 | 10,0 % | 48 | 10,9 % | +30,70 % |
Japan
0,5
%
| 1 | 0,3 % | 2 | 0,5 % | +91,56 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Emil Kakkis
FOU | Founder | 63 | 22/04/10 |
Howard Horn
DFI | Director of Finance/CFO | 47 | 16/10/23 |
Eric Crombez
CTO | Chief Tech/Sci/R&D Officer | - | 01/11/17 |
Dennis Huang
CTO | Chief Tech/Sci/R&D Officer | 59 | 01/05/15 |
Chief Tech/Sci/R&D Officer | 75 | 01/11/17 | |
Joshua Higa
IRC | Investor Relations Contact | - | - |
Ernie Meyer
HRO | Human Resources Officer | 60 | 01/09/20 |
Karah Parschauer
LAW | General Counsel | 46 | 20/06/16 |
Vimal Srivastava
PRN | Corporate Officer/Principal | 58 | 01/08/11 |
Erik Harris
PRN | Corporate Officer/Principal | 54 | 01/01/17 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Deborah Dunsire
BRD | Director/Board Member | 61 | 06/04/17 |
Emil Kakkis
FOU | Founder | 63 | 22/04/10 |
Daniel Welch
CHM | Chairman | 66 | 08/04/15 |
Matthew Fust
BRD | Director/Board Member | 59 | 01/01/14 |
Michael Narachi
BRD | Director/Board Member | 64 | 20/02/15 |
Corazon Sanders
BRD | Director/Board Member | 67 | 29/06/21 |
Shehnaaz Suliman
BRD | Director/Board Member | 52 | 30/01/19 |
Amrit Ray
BRD | Director/Board Member | 51 | 19/04/22 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 82 345 246 | 78 952 618 ( 95,88 %) | 9 559 ( 0,0116 %) | 95,88 % |
Información de la empresa
Sector
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
-7,40 % | 3645,82 M | |
-1,51 % | 104 mil M | |
+3,22 % | 97,42 mil M | |
+1,46 % | 22,2 mil M | |
-16,53 % | 21,23 mil M | |
-9,05 % | 18,33 mil M | |
-42,33 % | 16,35 mil M | |
-20,09 % | 15,06 mil M | |
+5,47 % | 13,98 mil M | |
+28,85 % | 11,66 mil M |
- Bolsa de valores
- Acciones
- Acción RARE
- Empresa Ultragenyx Pharmaceutical Inc.